{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:40:27Z","timestamp":1784684427357,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.intimp.2015.09.012","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T07:25:24Z","timestamp":1443338724000},"page":"663-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Anti-nicotine vaccines: Comparison of adjuvanted CRM 197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates"],"prefix":"10.1016","volume":"29","author":[{"given":"Michael J.","family":"McCluskie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Stead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Cartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshab","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari I.","family":"Finneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Merson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2015.09.012_bb0005","series-title":"Fact Sheet Number 339","article-title":"Tobacco","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.intimp.2015.09.012_bb0010","series-title":"The Top 10 Causes of Death: Fact Sheet Number 310","author":"World Health Organization","year":"2014"},{"issue":"6","key":"10.1016\/j.intimp.2015.09.012_bb0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5993\/AJHB.32.6.10","article-title":"Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis","volume":"32","author":"Nides","year":"2008","journal-title":"Am. J. Health Behav."},{"issue":"1","key":"10.1016\/j.intimp.2015.09.012_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1360-0443.2004.00540.x","article-title":"Shape of the relapse curve and long-term abstinence among untreated smokers","volume":"99","author":"Hughes","year":"2004","journal-title":"Addiction"},{"issue":"9629","key":"10.1016\/j.intimp.2015.09.012_bb0025","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(08)60871-5","article-title":"Tobacco addiction","volume":"371","author":"Hatsukami","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2015.09.012_bb0030","first-page":"11","article-title":"Therapeutic vaccines for nicotine dependence","volume":"8","author":"Maurer","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2015.09.012_bb0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599900-000000000-00000","article-title":"Nicotine vaccines to assist with smoking cessation: current status of research","volume":"72","author":"Raupach","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2015.09.012_bb0040","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/B978-0-12-420118-7.00014-7","article-title":"New directions in nicotine vaccine design and use","volume":"69","author":"Pentel","year":"2014","journal-title":"Adv. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2015.09.012_bb0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2015.09.012_bb0050","doi-asserted-by":"crossref","first-page":"e2547","DOI":"10.1371\/journal.pone.0002547","article-title":"A vaccine against nicotine for smoking cessation: a randomized controlled trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2015.09.012_bb0055","article-title":"Efficacy of the nicotine vaccine 3\u2032-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial","volume":"3","author":"Hoogsteder","year":"2014","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.intimp.2015.09.012_bb0060","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/ntr\/ntt003","article-title":"Niccine(R), a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial","volume":"15","author":"Tonstad","year":"2013","journal-title":"Nicotine Tob. Res."},{"issue":"4","key":"10.1016\/j.intimp.2015.09.012_bb0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bcp.2011.11.004","article-title":"Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities","volume":"83","author":"Pravetoni","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2015.09.012_bb0070","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.intimp.2008.07.001","article-title":"Enhanced immunogenicity of a bivalent nicotine vaccine","volume":"8","author":"Keyler","year":"2008","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2015.09.012_bb0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000063628","article-title":"Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell","volume":"69","author":"de Villiers","year":"2002","journal-title":"Respiration"},{"issue":"12","key":"10.1016\/j.intimp.2015.09.012_bb0080","doi-asserted-by":"crossref","first-page":"e82557","DOI":"10.1371\/journal.pone.0082557","article-title":"Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions","volume":"8","author":"Cornish","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.intimp.2015.09.012_bb0085","doi-asserted-by":"crossref","first-page":"e76557","DOI":"10.1371\/journal.pone.0076557","article-title":"Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice","volume":"8","author":"Pryde","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2015.09.012_bb0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.intimp.2013.03.021","article-title":"Enhancing immunogenicity of a 3\u2032aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates","volume":"16","author":"McCluskie","year":"2013","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2015.09.012_bb0095","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1021\/mp900213u","article-title":"A critical evaluation of a nicotine vaccine within a self-administration behavioral model","volume":"7","author":"Moreno","year":"2010","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.intimp.2015.09.012_bb0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.intimp.2015.02.030","article-title":"Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates","volume":"25","author":"McCluskie","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2015.09.012_bb0105","first-page":"406","article-title":"Preclinical development of a vaccine \u2018against smoking\u2019","volume":"25","author":"Cerny","year":"2002","journal-title":"Onkologie"},{"issue":"1","key":"10.1016\/j.intimp.2015.09.012_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4161\/hv.26635","article-title":"A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle","volume":"10","author":"Hu","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.intimp.2015.09.012_bb0115","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clpt.2005.08.007","article-title":"Safety and immunogenicity of a nicotine conjugate vaccine in current smokers","volume":"78","author":"Hatsukami","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2015.09.012_bb0120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/hum.2012.245","article-title":"Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine","volume":"24","author":"Rosenberg","year":"2013","journal-title":"Hum. Gene Ther."},{"issue":"7","key":"10.1016\/j.intimp.2015.09.012_bb0125","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200526285","article-title":"A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity","volume":"35","author":"Maurer","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2015.09.012_bb0130","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/jm501625j","article-title":"A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity","volume":"58","author":"Lockner","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2015.09.012_bb0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2015.09.012_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.1984.67","article-title":"Daily intake of nicotine during cigarette smoking","volume":"35","author":"Benowitz","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2015.09.012_bb0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-540-69248-5_2","article-title":"Nicotine chemistry, metabolism, kinetics and biomarkers","volume":"192","author":"Benowitz","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2015.09.012_bb0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Broker","year":"2011","journal-title":"Biologicals"},{"issue":"6","key":"10.1016\/j.intimp.2015.09.012_bb0155","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B\u00ae HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2015.09.012_bb0160","doi-asserted-by":"crossref","first-page":"e22271","DOI":"10.1371\/journal.pone.0022271","article-title":"Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1\/Alhydrogel+CPG 7909","volume":"6","author":"Duncan","year":"2011","journal-title":"PLoS One"},{"issue":"31","key":"10.1016\/j.intimp.2015.09.012_bb0165","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1016\/j.vaccine.2009.04.077","article-title":"A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1\/Alhydrogel with CPG 7909, using two different formulations and dosing intervals","volume":"27","author":"Ellis","year":"2009","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.intimp.2015.09.012_bb0170","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax\u00ae (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.intimp.2015.09.012_bb0175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.vaccine.2004.07.014","article-title":"Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response","volume":"23","author":"Siegrist","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2015.09.012_bb0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(02)00228-6","article-title":"Recognition of pathogen-associated molecular patterns by TLR family","volume":"85","author":"Akira","year":"2003","journal-title":"Immunol. Lett."},{"issue":"21\u201322","key":"10.1016\/j.intimp.2015.09.012_bb0185","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","article-title":"CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques","volume":"22","author":"Klinman","year":"2004","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2015.09.012_bb0190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","article-title":"A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity","volume":"25","author":"Ambuhl","year":"2007","journal-title":"J. Hypertens."},{"issue":"9615","key":"10.1016\/j.intimp.2015.09.012_bb0195","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(08)60381-5","article-title":"Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study","volume":"371","author":"Tissot","year":"2008","journal-title":"Lancet"},{"issue":"1579","key":"10.1016\/j.intimp.2015.09.012_bb0200","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1098\/rstb.2011.0103","article-title":"Therapeutic vaccines for chronic diseases: successes and technical challenges","volume":"366","author":"Bachmann","year":"2011","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.intimp.2015.09.012_bb0205","unstructured":"Cytos Biotechnology Ltd. Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb. Cytos_Press_E_091110. 11-10-0009, 2013."},{"issue":"45","key":"10.1016\/j.intimp.2015.09.012_bb0210","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2005.06.024","article-title":"TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)","volume":"23","author":"Weeratna","year":"2005","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.intimp.2015.09.012_bb0215","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.dci.2009.12.018","article-title":"Co-stimulation with TLR7\/8 and TLR9 agonists induce down-regulation of innate immune responses in sheep blood mononuclear and B cells","volume":"34","author":"Booth","year":"2010","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/j.intimp.2015.09.012_bb0220","article-title":"Molecular attributes of conjugate antigen in NIC7 anti-nicotine vaccine influence avidity and function of antibodies induced in mice and non-human primates","author":"McCluskie","year":"2013"},{"issue":"4","key":"10.1016\/j.intimp.2015.09.012_bb0225","doi-asserted-by":"crossref","first-page":"e1000048","DOI":"10.1371\/journal.pcbi.1000048","article-title":"A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach","volume":"4","author":"Wang","year":"2008","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.intimp.2015.09.012_bb0230","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/1471-2105-11-568","article-title":"Peptide binding predictions for HLA DR DP and DQ molecules","volume":"11","author":"Wang","year":"2010","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"10.1016\/j.intimp.2015.09.012_bb0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0022-3565(24)37941-8","article-title":"Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers","volume":"288","author":"Jones","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2015.09.012_bb0240","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1176\/appi.ajp.2012.12060793","article-title":"Effect of a nicotine vaccine on nicotine binding to beta2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers","volume":"170","author":"Esterlis","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.intimp.2015.09.012_bb0245","doi-asserted-by":"crossref","DOI":"10.4161\/hv.4.3.5318","article-title":"Novel vaccines and adjuvant systems: the utility of animal models for predicting immunogenicity in humans","volume":"4","author":"Davis","year":"2007","journal-title":"Hum. Vaccin."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915301156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915301156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:41:00Z","timestamp":1748637660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915301156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1567576915301156"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.09.012","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}